Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
12 03 2020
Historique:
pubmed: 10 10 2019
medline: 1 9 2020
entrez: 10 10 2019
Statut: ppublish

Résumé

The therapeutic success of peptidic GLP-1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for orally bioavailable small molecules that can activate the GLP-1 receptor (GLP-1R) as a well-validated target for T2DM. Here, the discovery and characterization of a potent and selective positive allosteric modulator (PAM) for GLP-1R based on a 3,4,5,6-tetrahydro-1

Identifiants

pubmed: 31596080
doi: 10.1021/acs.jmedchem.9b01071
doi:

Substances chimiques

Blood Glucose 0
Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2292-2307

Auteurs

María Méndez (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Hans Matter (H)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Elisabeth Defossa (E)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Michael Kurz (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Sylvain Lebreton (S)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Ziyu Li (Z)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Matthias Lohmann (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Matthias Löhn (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Hartmut Mors (H)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Michael Podeschwa (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Nils Rackelmann (N)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Jens Riedel (J)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Pavel Safar (P)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

David S Thorpe (DS)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Matthias Schäfer (M)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Dietmar Weitz (D)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Kristin Breitschopf (K)

Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH